EcoDrugPlus

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSDARG00000024746
Gene Symbol: HSP90AA1.2
5 Cross references
317 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSDARG00000029150
Gene Symbol: HSP90AB1
5 Cross references
358 Possible Orthologues:

High Mobility Group Box 1a

Ensembl ID : ENSDARG00000099175
Gene Symbol: HMGB1A
32 Enzyme and pathways 5 Cross references
454 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSDARG00000030479
Gene Symbol: HMGB1B
5 Cross references
510 Possible Orthologues:

Histamine Receptor H2a

Ensembl ID : ENSDARG00000107444
Gene Symbol: HRH2A
5 Cross references
192 Possible Orthologues:

Histone Deacetylase 1

Ensembl ID : ENSDARG00000015427
Gene Symbol: HDAC1
43 Enzyme and pathways 5 Cross references
307 Possible Orthologues:

Histone Deacetylase 10

Ensembl ID : ENSDARG00000086458
Gene Symbol: HDAC10
7 Enzyme and pathways 5 Cross references
181 Possible Orthologues:

Histone Deacetylase 11

Ensembl ID : ENSDARG00000087573
Gene Symbol: HDAC11
4 Enzyme and pathways 5 Cross references
200 Possible Orthologues:

Histone Deacetylase 4

Ensembl ID : ENSDARG00000098349
Gene Symbol: HDAC4
12 Enzyme and pathways 5 Cross references
202 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSDARG00000075139
Gene Symbol: HDAC5
4 Enzyme and pathways 5 Cross references
196 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSDARG00000008384
Gene Symbol: HDAC6
11 Enzyme and pathways 5 Cross references
182 Possible Orthologues:

Histone Deacetylase 7a

Ensembl ID : ENSDARG00000105179
Gene Symbol: HDAC7A
4 Enzyme and pathways 3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).